In Brussels, July 9th, 2024, Dr. Pascal Piedbois assumed a pivotal role at One2Treat, tasked with ensuring their offerings meet the rigorous standards of both patients and clinical sponsors. Founded by Marc Buyse, One2Treat is pioneering an innovative approach aimed at reducing trial sample sizes and accelerating patient access to new treatments. Their software integrates multiple clinical outcomes crucial to patients right from the study design phase, employing robust statistical methodologies. Dr. Piedbois, a distinguished figure in Medical Oncology with over 30 years of experience, brings a wealth of expertise from academia and industry, including leadership roles at Paris University and prominent pharmaceutical companies like AstraZeneca and Bristol Myers Squibb.
Sebastien Coppe, CEO of One2Treat, underscores Pascal’s strategic role, emphasizing the industry’s need to integrate diverse patient-relevant outcomes into holistic treatment assessments. He highlights that current clinical studies often underutilize valuable data by focusing narrowly on primary endpoints, failing to capture the full impact of treatments on patients. Pascal’s leadership is expected to drive significant transformations in clinical trial design, aligning studies more closely with patient priorities such as quality of life.
Dr. Pascal Piedbois stresses the importance of early engagement with stakeholders—patients, sponsors, regulators, and payers—in shaping clinical trial designs. This collaborative approach, he argues, allows for better alignment on primary endpoints early in the study process, enhancing trial efficiency and speeding up the path to market for new therapies. His goal is to ensure that clinical trials accurately reflect what matters most to patients, thereby improving treatment outcomes and patient satisfaction.
Marc Buyse, Founder of One2Treat, expresses his enthusiasm for Pascal’s appointment, citing their longstanding collaboration and Pascal’s deep medical expertise as catalysts for advancing a patient-centric agenda in clinical research. He believes Pascal’s insights will accelerate the adoption of a multi-dimensional approach that resonates strongly with medical leaders and enhances the overall efficacy of treatments brought to market.
Dr. Pascal Piedbois further elaborates on One2Treat’s broader impact, emphasizing their role in fostering a more transparent and efficient transition from drug development to market access. By employing rigorous quantitative methods to assess treatment effects comprehensively, One2Treat aims to bridge the gap between clinical research and health technology assessments, offering robust benefit-risk evaluations that align closely with patient needs.
About One2Treat:
One2Treat collaborates closely with biopharmaceutical firms, providing transformative insights into clinical trial design, analysis, and market access evaluations to support holistic treatment decisions. Driven by a commitment to patient-centricity, One2Treat harnesses advanced statistical methodologies and software solutions to integrate diverse efficacy and safety outcomes into unified measures. This innovation enables the estimation of Net Treatment Benefits aligned with patient preferences, heralding a new era of personalized healthcare. One2Treat empowers sponsors to optimize registration trials by incorporating multiple patient-relevant outcomes into primary analyses, resulting in smaller, more targeted trials and accelerated R&D timelines. Additionally, their comprehensive benefit-risk assessments and patient-centric analyses facilitate smoother market access, aligning with evolving healthcare needs. As initiatives to prioritize patient preferences in treatment development gain momentum, One2Treat’s pioneering trial designs are poised to set a new industry standard.
For more information on One2Treat’s innovative solutions and their transformative impact on clinical trial design and market access, visit www.one2treat.com and join the movement towards patient-centered healthcare.
